Physician profile
Derek Glenn Eiflander
NPI 1881581510
$701.08
in general payments reported to CMS, 2019-2025
10 companies · $701 in 2025
The $701 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $701.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $196.39 | 2025 | Caplyta |
| Gilead Sciences, INC. | $148.13 | 2025 | |
| Viiv Healthcare Company | $115.63 | 2025 | Dovato, Rukobia, Cabenuva |
| Theratechnologies INC. | $79.02 | 2025 | Trogarzo, Egrifta |
| Merck Sharp & Dohme LLC | $48.16 | 2025 | Pifeltro, Gardasil 9, Capvaxive |
| Abbvie INC. | $38.10 | 2025 | |
| Novo Nordisk INC | $22.38 | 2025 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $19.19 | 2025 | Cologuard Collection Kit |
| Abbott Laboratories | $17.25 | 2025 | Freestyle Libre 3 |
| Amgen INC. | $16.83 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Eiflander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.